Annette North joined Turning Point Therapeutics in April 2019 as executive vice president and general counsel. Ms. North also serves as company secretary. She brings more than 25 years of experience serving biotechnology companies from inception through private and public financings, business development and acquisitions. Ms. North previously served as a senior executive and general counsel for Kura Oncology and Wellspring Biosciences. Prior to Kura, Ms. North served as senior vice president and general counsel at Ambit Biosciences from initial public offering through acquisition by Daiichi Sankyo. Prior to Ambit, she served as an independent legal counsel to a number of life sciences companies and held legal roles at SGX Pharmaceuticals, Axys Pharmaceuticals, and Sequana Therapeutics. Ms. North began her career at law firms in Melbourne, Australia and London, England. She earned her Bachelor of Laws and Bachelor of Commerce degrees from Melbourne University in Australia, and is a member of the State Bar of California.